CR20200532A - Compuestos de heteroarilo tetracíclicos - Google Patents
Compuestos de heteroarilo tetracíclicosInfo
- Publication number
- CR20200532A CR20200532A CR20200532A CR20200532A CR20200532A CR 20200532 A CR20200532 A CR 20200532A CR 20200532 A CR20200532 A CR 20200532A CR 20200532 A CR20200532 A CR 20200532A CR 20200532 A CR20200532 A CR 20200532A
- Authority
- CR
- Costa Rica
- Prior art keywords
- heteroaryl compounds
- tetracyclic heteroaryl
- tetracyclic
- relates
- compounds
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
<p>La memoria descriptiva se refiere a compuestos de Fórmula (I) y sales farmacéuticamente aceptables de los mismos. La memoria descriptiva también se refiere a procesos e intermedios usados para su preparación, a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de trastornos proliferativos celulares.</p>
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862668321P | 2018-05-08 | 2018-05-08 | |
| US201862754814P | 2018-11-02 | 2018-11-02 | |
| PCT/EP2019/061754 WO2019215203A1 (en) | 2018-05-08 | 2019-05-07 | Tetracyclic heteroaryl compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200532A true CR20200532A (es) | 2020-12-23 |
Family
ID=66484036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200532A CR20200532A (es) | 2018-05-08 | 2019-05-07 | Compuestos de heteroarilo tetracíclicos |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11407765B2 (es) |
| EP (1) | EP3790884A1 (es) |
| JP (1) | JP7138724B2 (es) |
| KR (1) | KR20210006948A (es) |
| CN (1) | CN112074520A (es) |
| AU (1) | AU2019267008B2 (es) |
| BR (1) | BR112020021467A2 (es) |
| CA (1) | CA3098261A1 (es) |
| CL (1) | CL2020002866A1 (es) |
| CO (1) | CO2020013564A2 (es) |
| CR (1) | CR20200532A (es) |
| DO (1) | DOP2020000201A (es) |
| EC (1) | ECSP20070854A (es) |
| JO (1) | JOP20200281A1 (es) |
| MA (1) | MA52560A (es) |
| MX (1) | MX2020011910A (es) |
| NI (1) | NI202000078A (es) |
| PE (1) | PE20211795A1 (es) |
| PH (1) | PH12020551870A1 (es) |
| SG (1) | SG11202010953QA (es) |
| TW (1) | TW202012415A (es) |
| UY (1) | UY38221A (es) |
| WO (1) | WO2019215203A1 (es) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068695T2 (hu) | 2018-05-08 | 2025-01-28 | Nippon Shinyaku Co Ltd | Azabenzimidazol vegyületek és gyógyszerek |
| US12065430B2 (en) | 2018-10-26 | 2024-08-20 | Taiho Pharmaceutical Co., Ltd. | Indazole compound or salt thereof |
| AU2020231045B2 (en) * | 2019-03-05 | 2023-03-16 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| KR20220012255A (ko) * | 2019-04-28 | 2022-02-03 | 젠플리트 테라퓨틱스 (상하이) 아이엔씨. | 옥사아자퀴나졸린-7(8h)-케톤 화합물, 이의 제조 방법 및 이의 약학적 응용 |
| CR20220230A (es) | 2019-10-28 | 2022-06-15 | Merck Sharp & Dohme | Inhibidores de pequeñas moléculas de mutante g12c de kras |
| CN120988055A (zh) | 2019-11-04 | 2025-11-21 | 锐新医药公司 | Ras抑制剂 |
| US11739074B2 (en) | 2019-11-04 | 2023-08-29 | Revolution Medicines, Inc. | Ras inhibitors |
| CA3160142A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4059933A4 (en) | 2019-11-13 | 2023-11-15 | Nippon Shinyaku Co., Ltd. | AZABENZIMIDAZOLE COMPOUND AND DRUG |
| CN114980976A (zh) * | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| RS63719B1 (sr) * | 2019-12-11 | 2022-11-30 | Lilly Co Eli | Kras g12c inhibitori |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| TWI799871B (zh) * | 2020-05-27 | 2023-04-21 | 大陸商勁方醫藥科技(上海)有限公司 | 三環并環類化合物，其製法與醫藥上的用途 |
| TW202214253A (zh) | 2020-06-18 | 2022-04-16 | 美商銳新醫藥公司 | 延遲、預防及治療對ｒａｓ抑制劑之後天抗性之方法 |
| CN113980032B (zh) * | 2020-07-27 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
| MX2023001682A (es) * | 2020-08-12 | 2023-02-22 | Genentech Inc | Sintesis de compuestos de quinazolina. |
| JP2023540270A (ja) | 2020-08-28 | 2023-09-22 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環式化合物およびその使用 |
| AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| MX2023003338A (es) | 2020-09-23 | 2023-06-14 | Erasca Inc | Piridonas y pirimidonas tricíclicas. |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN114685531B (zh) * | 2020-12-25 | 2024-10-22 | 武汉誉祥医药科技有限公司 | 四并环化合物及其药物组合物和应用 |
| JP2024506029A (ja) * | 2021-02-09 | 2024-02-08 | ジェネンテック， インコーポレイテッド | 四環系オキサゼピン化合物及びその使用 |
| CN117083280A (zh) * | 2021-03-07 | 2023-11-17 | 北京加科思新药研发有限公司 | Kras g12d抑制剂的稠环衍生物 |
| JP2024510022A (ja) * | 2021-03-17 | 2024-03-05 | ▲勁▼方医▲薬▼科技（上海）有限公司 | ピリミジン縮合環系化合物、その製造方法、及び使用 |
| CN117083281A (zh) * | 2021-03-24 | 2023-11-17 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| WO2022206723A1 (zh) * | 2021-03-30 | 2022-10-06 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| US20240383915A1 (en) * | 2021-04-08 | 2024-11-21 | Genentech, Inc. | Oxazepine compounds and uses thereof in the treatment of cancer |
| IL308193A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors |
| TW202309053A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| MX2023015533A (es) * | 2021-06-21 | 2024-01-23 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. |
| CA3224284A1 (en) * | 2021-07-02 | 2023-01-05 | Feng Wang | Kras g12d inhibitor and use thereof |
| CN117677624A (zh) * | 2021-07-19 | 2024-03-08 | 上海艾力斯医药科技股份有限公司 | 新型吡啶并嘧啶衍生物 |
| WO2023001141A1 (en) * | 2021-07-23 | 2023-01-26 | Shanghai Zion Pharma Co. Limited | Kras g12d inhibitors and uses thereof |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| JP2024532374A (ja) | 2021-09-01 | 2024-09-05 | ノバルティス アーゲー | Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用 |
| EP4389751A1 (en) | 2021-09-03 | 2024-06-26 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| KR20240070619A (ko) * | 2021-09-27 | 2024-05-21 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | 폴리사이클릭 융합 고리 유도체 및 이의 용도 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023066371A1 (zh) * | 2021-10-22 | 2023-04-27 | 江苏恒瑞医药股份有限公司 | 含氮的四环化合物、其制备方法及其在医药上的应用 |
| CN118176198A (zh) * | 2021-11-01 | 2024-06-11 | 江苏恒瑞医药股份有限公司 | 含氮的四环化合物、其制备方法及其在医药上的应用 |
| WO2023103906A1 (zh) * | 2021-12-07 | 2023-06-15 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| US20250282782A1 (en) | 2021-12-17 | 2025-09-11 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN118434422A (zh) | 2021-12-28 | 2024-08-02 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和rasg12c抑制剂的组合 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN114539073A (zh) * | 2022-02-18 | 2022-05-27 | 郑州萃智医药科技有限公司 | 3-溴-2-氯-4,6-二氟苯胺的合成方法 |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| WO2023172737A1 (en) | 2022-03-11 | 2023-09-14 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2023225302A1 (en) | 2022-05-19 | 2023-11-23 | Genentech, Inc. | Aza-tetracyclic oxazepine compounds and uses thereof |
| JP2025521232A (ja) | 2022-06-10 | 2025-07-08 | レボリューション メディシンズ インコーポレイテッド | 大環状ｒａｓ阻害剤 |
| KR20250060956A (ko) | 2022-08-05 | 2025-05-07 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| EP4568973A1 (en) * | 2022-08-11 | 2025-06-18 | BeiGene Switzerland GmbH | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2024041621A1 (en) * | 2022-08-25 | 2024-02-29 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| WO2024138486A1 (en) * | 2022-12-29 | 2024-07-04 | Nikang Therapeutics, Inc. | Tetracyclic derivatives as kras inhibitors |
| JP2025532125A (ja) * | 2022-09-23 | 2025-09-29 | アイディーエンス カンパニー リミテッド | 新規なテトラヘテロサイクル化合物 |
| WO2024063576A1 (ko) * | 2022-09-23 | 2024-03-28 | 일동제약(주) | Kras 저해 물질로서 신규한 퀴나졸린 화합물 |
| AU2023363515A1 (en) * | 2022-10-18 | 2025-04-17 | Idience Co., Ltd. | Novel triheterocyclic compounds |
| JP2026504244A (ja) | 2022-11-09 | 2026-02-04 | レヴォリューション・メディスンズ，インコーポレイテッド | 化合物、複合体、ならびにそれらの調製方法及びそれらの使用方法 |
| WO2024120419A1 (en) * | 2022-12-06 | 2024-06-13 | Zai Lab (Shanghai) Co., Ltd. | Fused tetracyclic compounds as kras g12d modulators and uses thereof |
| TW202430184A (zh) * | 2022-12-20 | 2024-08-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Kras g12d抑制劑的結晶形式及製備方法 |
| WO2024149214A1 (en) * | 2023-01-10 | 2024-07-18 | Nikang Therapeutics, Inc. | Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway |
| CN120548318A (zh) * | 2023-01-18 | 2025-08-26 | 苏州赞荣医药科技有限公司 | Kras g12d抑制剂和其用途 |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| EP4688790A1 (en) | 2023-04-07 | 2026-02-11 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024251689A1 (en) | 2023-04-14 | 2025-11-27 | Astrazeneca Ab | Combinations of kras inhibitor and atr inhibitor for the treatment of cancer |
| KR20250169290A (ko) | 2023-04-14 | 2025-12-02 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법 |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| CN120957997A (zh) * | 2023-04-21 | 2025-11-14 | 江苏恒瑞医药股份有限公司 | 一种含氮四环化合物的结晶形式及其制备方法 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| TW202500126A (zh) | 2023-05-24 | 2025-01-01 | 美商金橘生物科技公司 | 雜環化合物及其用途 |
| WO2024248123A1 (ja) | 2023-06-02 | 2024-12-05 | 第一三共株式会社 | 抗ｈｅｒ３抗体－薬物コンジュゲートとｒａｓｇ１２ｃ阻害剤の組み合わせ |
| AU2024307234A1 (en) | 2023-06-30 | 2026-01-29 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
| TW202523291A (zh) * | 2023-11-02 | 2025-06-16 | 美商金橘生物科技公司 | 降解劑及其用途 |
| WO2025171055A1 (en) | 2024-02-06 | 2025-08-14 | Kumquat Biosciences Inc. | Heterocyclic conjugates and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025230971A1 (en) | 2024-04-30 | 2025-11-06 | Kumquat Biosciences Inc. | Macrocyclic heterocycles as anticancer agents |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013155223A1 (en) | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
| EP3401314B1 (en) | 2013-03-15 | 2023-11-08 | Araxes Pharma LLC | Covalent inhibitors of kras g12c |
| CA2926328C (en) | 2013-10-10 | 2022-11-29 | Araxes Pharma Llc | Substituted quinazolinyl and quinolinyl derivatives and pharmaceutical compositions thereof useful as inhibitors of kras g12c |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| EP3197870B1 (en) | 2014-09-25 | 2020-08-19 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EA201792214A1 (ru) | 2015-04-10 | 2018-01-31 | Араксис Фарма Ллк | Соединения замещенного хиназолина |
| CA2982360A1 (en) | 2015-04-15 | 2016-10-20 | Liansheng Li | Fused-tricyclic inhibitors of kras and methods of use thereof |
| MX388781B (es) | 2015-07-22 | 2025-03-20 | Araxes Pharma Llc | Compuestos de quinazolina sustituido y su uso como inhibidores de proteínas kras, hras y/o nras mutantes g12c. |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356354A1 (en) * | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356351A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| US11267812B2 (en) | 2016-05-18 | 2022-03-08 | Mirati Therapeutics, Inc. | KRAS G12C inhibitors |
| CN110036010A (zh) | 2016-09-29 | 2019-07-19 | 亚瑞克西斯制药公司 | Kras g12c突变蛋白的抑制剂 |
| WO2018068017A1 (en) | 2016-10-07 | 2018-04-12 | Araxes Pharma Llc | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| SG11201906223TA (en) | 2016-12-22 | 2019-08-27 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| CN110382483A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的n-杂环化合物及其使用方法 |
| US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 |
| US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| JOP20190186A1 (ar) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| AR111776A1 (es) * | 2017-05-11 | 2019-08-21 | Astrazeneca Ab | Heteroarilos inhibidores de las proteínas ras mutantes de g12c |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| EP3630747A1 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| WO2018218071A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
| UY37870A (es) | 2017-09-08 | 2019-03-29 | Amgen Inc | Inhibidores de kras g12c y métodos para utilizarlos campo de la invención |
| CA3082579A1 (en) | 2017-11-15 | 2019-05-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| TW201938561A (zh) | 2017-12-08 | 2019-10-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
| TW201942116A (zh) | 2018-02-09 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌劑之四氫喹唑啉衍生物 |
-
2019
- 2019-05-03 TW TW108115329A patent/TW202012415A/zh unknown
- 2019-05-07 CR CR20200532A patent/CR20200532A/es unknown
- 2019-05-07 MA MA052560A patent/MA52560A/fr unknown
- 2019-05-07 JP JP2020560800A patent/JP7138724B2/ja active Active
- 2019-05-07 US US17/053,400 patent/US11407765B2/en active Active
- 2019-05-07 MX MX2020011910A patent/MX2020011910A/es unknown
- 2019-05-07 SG SG11202010953QA patent/SG11202010953QA/en unknown
- 2019-05-07 KR KR1020207035034A patent/KR20210006948A/ko not_active Withdrawn
- 2019-05-07 PE PE2020001766A patent/PE20211795A1/es unknown
- 2019-05-07 JO JOP/2020/0281A patent/JOP20200281A1/ar unknown
- 2019-05-07 CA CA3098261A patent/CA3098261A1/en active Pending
- 2019-05-07 EP EP19723368.7A patent/EP3790884A1/en not_active Withdrawn
- 2019-05-07 BR BR112020021467-1A patent/BR112020021467A2/pt not_active Application Discontinuation
- 2019-05-07 AU AU2019267008A patent/AU2019267008B2/en not_active Expired - Fee Related
- 2019-05-07 CN CN201980030143.8A patent/CN112074520A/zh active Pending
- 2019-05-07 WO PCT/EP2019/061754 patent/WO2019215203A1/en not_active Ceased
- 2019-05-08 UY UY38221A patent/UY38221A/es not_active Application Discontinuation
-
2020
- 2020-10-28 CO CONC2020/0013564A patent/CO2020013564A2/es unknown
- 2020-11-04 DO DO2020000201A patent/DOP2020000201A/es unknown
- 2020-11-05 PH PH12020551870A patent/PH12020551870A1/en unknown
- 2020-11-05 CL CL2020002866A patent/CL2020002866A1/es unknown
- 2020-11-06 EC ECSENADI202070854A patent/ECSP20070854A/es unknown
- 2020-11-06 NI NI202000078A patent/NI202000078A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019267008A1 (en) | 2021-01-07 |
| ECSP20070854A (es) | 2020-12-31 |
| KR20210006948A (ko) | 2021-01-19 |
| AU2019267008B2 (en) | 2022-02-17 |
| SG11202010953QA (en) | 2020-12-30 |
| CL2020002866A1 (es) | 2021-02-12 |
| PE20211795A1 (es) | 2021-09-09 |
| DOP2020000201A (es) | 2020-11-30 |
| CA3098261A1 (en) | 2019-11-14 |
| JOP20200281A1 (ar) | 2020-11-05 |
| BR112020021467A2 (pt) | 2021-01-19 |
| MX2020011910A (es) | 2021-01-29 |
| PH12020551870A1 (en) | 2021-07-26 |
| CO2020013564A2 (es) | 2020-11-10 |
| MA52560A (fr) | 2021-03-17 |
| TW202012415A (zh) | 2020-04-01 |
| CN112074520A (zh) | 2020-12-11 |
| US20210221823A1 (en) | 2021-07-22 |
| JP7138724B2 (ja) | 2022-09-16 |
| EP3790884A1 (en) | 2021-03-17 |
| WO2019215203A1 (en) | 2019-11-14 |
| NI202000078A (es) | 2021-02-16 |
| JP2021532061A (ja) | 2021-11-25 |
| UY38221A (es) | 2019-10-31 |
| US11407765B2 (en) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
| PH12021552083A1 (en) | Fused tricyclic compounds useful as anticancer agents | |
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| ZA202400595B (en) | Spirocyclic compounds | |
| PH12022551585A1 (en) | Substituted tricyclic compounds | |
| MX393395B (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo. | |
| MY204421A (en) | Pyruvate kinase activators for use in treating blood disorders | |
| PH12019501724A1 (en) | Estrogen receptor modulators | |
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| MX2014010925A (es) | Compuesto de heterociclilo. | |
| MX389592B (es) | Moduladores alostericos positivos del receptor m1 muscarinico | |
| PH12021550048A1 (en) | Selective estrogen receptor degraders. | |
| PH12016501764A1 (en) | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators | |
| NZ764004A (en) | Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators | |
| MX2016011900A (es) | Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2. | |
| EA202092600A1 (ru) | Тетрациклические гетероарильные соединения | |
| EA201991734A1 (ru) | Модуляторы рецептора эстрогена | |
| EA202192366A1 (ru) | Конденсированные трициклические соединения, применимые в качестве противораковых средств | |
| EA201990943A1 (ru) | 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА | |
| NZ764561A (en) | Substituted azacycles as muscarinic m1 receptor positive allosteric modulators |